These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Pharmacotherapy of sepsis]. Guzzo I; Morabito S; Stucchi R; Poli G; Fumagalli R G Ital Nefrol; 2006; 23 Suppl 36():S79-86. PubMed ID: 17068734 [TBL] [Abstract][Full Text] [Related]
25. Immunomodulation in sepsis: state of the art and future perspective. Antonopoulou A; Giamarellos-Bourboulis EJ Immunotherapy; 2011 Jan; 3(1):117-28. PubMed ID: 21174562 [TBL] [Abstract][Full Text] [Related]
26. Sepsis and septic shock: pathophysiological and cardiovascular background as basis for therapy. De Kock I; Van Daele C; Poelaert J Acta Clin Belg; 2010; 65(5):323-9. PubMed ID: 21128559 [TBL] [Abstract][Full Text] [Related]
27. [Severe sepsis and septic shock]. Delaloye J; Baumgartner JD; Calandra T Rev Med Suisse; 2006 Apr; 2(60):896-8, 900-2. PubMed ID: 16673720 [TBL] [Abstract][Full Text] [Related]
29. Recent advances in the pathophysiology and molecular basis of sepsis-associated organ dysfunction: Novel therapeutic implications and challenges. Hattori Y; Hattori K; Suzuki T; Matsuda N Pharmacol Ther; 2017 Sep; 177():56-66. PubMed ID: 28232275 [TBL] [Abstract][Full Text] [Related]
30. Optimizing antimicrobial therapy in sepsis and septic shock. Kumar A Crit Care Clin; 2009 Oct; 25(4):733-51, viii. PubMed ID: 19892250 [TBL] [Abstract][Full Text] [Related]
31. Pathophysiologic basis of sepsis: considerations for future strategies of intervention. Glauser MP Crit Care Med; 2000 Sep; 28(9 Suppl):S4-8. PubMed ID: 11007189 [TBL] [Abstract][Full Text] [Related]
32. Sepsis target validation for repurposing and combining complement and immune checkpoint inhibition therapeutics. Rodrigues PRS; Picco N; Morgan BP; Ghazal P Expert Opin Drug Discov; 2021 May; 16(5):537-551. PubMed ID: 33206027 [No Abstract] [Full Text] [Related]
33. The race against the "septic shark". Westphal M; Kampmeier T Crit Care; 2015; 19 Suppl 3(Suppl 3):S11. PubMed ID: 26728320 [TBL] [Abstract][Full Text] [Related]
34. The efficacy of procalcitonin as a biomarker in the management of sepsis: slaying dragons or tilting at windmills? Sridharan P; Chamberlain RS Surg Infect (Larchmt); 2013 Dec; 14(6):489-511. PubMed ID: 24274059 [TBL] [Abstract][Full Text] [Related]
35. Barriers to the effective treatment of sepsis: antimicrobial agents, sepsis definitions, and host-directed therapies. Lyle NH; Pena OM; Boyd JH; Hancock RE Ann N Y Acad Sci; 2014 Sep; 1323():101-14. PubMed ID: 24797961 [TBL] [Abstract][Full Text] [Related]
36. [Sepsis. Update on pathophysiology, diagnostics and therapy]. Bauer M; Brunkhorst F; Welte T; Gerlach H; Reinhart K Anaesthesist; 2006 Aug; 55(8):835-45. PubMed ID: 16810538 [TBL] [Abstract][Full Text] [Related]
37. Sepsis: the inflammatory foundation of pathophysiology and therapy. Li J; Carr B; Goyal M; Gaieski DF Hosp Pract (1995); 2011 Aug; 39(3):99-112. PubMed ID: 21881397 [TBL] [Abstract][Full Text] [Related]
38. Emerging Adjunctive Approach for the Treatment of Sepsis: Vitamin C and Thiamine. Badeaux JE; Martin JB Crit Care Nurs Clin North Am; 2018 Sep; 30(3):343-351. PubMed ID: 30098738 [TBL] [Abstract][Full Text] [Related]
39. Endotoxin in the pathogenesis of sepsis. Marshall JC Contrib Nephrol; 2010; 167():1-13. PubMed ID: 20519894 [TBL] [Abstract][Full Text] [Related]
40. Could Biomarkers Direct Therapy for the Septic Patient? Sims CR; Nguyen TC; Mayeux PR J Pharmacol Exp Ther; 2016 May; 357(2):228-39. PubMed ID: 26857961 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]